文献速递冠心病外科

非接触大隐静脉复合桥15年通畅率与18年临床结局

Fifteen-year patency and 18-year clinical outcomes after surgical revascularization using saphenous vein composite grafts to total arterial grafts.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-05-02

本研究比较了基于左乳内动脉的非接触大隐静脉复合桥与全动脉复合桥行冠脉搭桥的远期效果。

要点

  • 非接触大隐静脉复合桥15年通畅率91.7%,与全动脉桥84.8%无显著差异
  • 两组18年生存率和主要不良心脏事件累积发生率无显著差异
  • 倾向性评分匹配176对后结论一致,支持非接触大隐静脉复合桥作为替代选择

核心结论

  • 使用非接触大隐静脉复合桥行CABG在15年通畅率和18年临床结局方面与全动脉复合桥相当。

研究设计与样本

  • 非接触大隐静脉复合桥组215例,全动脉复合桥组419例,共纳入634例患者(平均年龄65.1±8.9岁,男455例、女179例)。
  • 平均远端吻合口数3.3±0.8,采用竞争风险校正评估15年通畅率,并进行倾向性评分匹配分析。

主要发现

  • 两组总体桥血管和复合桥血管的15年绝对通畅率均无显著差异。
  • 两组18年总生存率和主要不良心脏事件累积发生率均无显著差异。
  • 倾向性评分匹配产生176对患者,匹配后两组15年通畅率和18年临床结局仍无显著差异。

临床怎么用

  • 对于需要多支血管重建的CABG患者,非接触大隐静脉复合桥可作为全动脉复合桥的替代选择。
  • 非接触大隐静脉复合桥的远期通畅率和临床结局与全动脉桥相当,支持其在特定患者中的应用。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare 15-year graft patency and 18-year clinical outcomes after coronary artery bypass grafting (CABG) using no-touch saphenous vein (NT-SV) composite grafts based on the left internal thoracic artery and after CABG using arterial composite grafts. METHODS: Patients who underwent primary isolated off-pump CABG between January 2006 and December 2009 were screened for study eligibility. The NT-SV composite grafts were used in 215 patients (SV group). Fifteen-year graft patency rates and 18-year clinical outcomes were evaluated. These results were compared with 419 patients who underwent surgery using total arterial composite grafts (TAC group). RESULTS: A total of 634 patients (mean age, 65.1 ± 8.9 years, 455 males and 179 females) were enrolled. The average number of distal anastomoses was 3.3 ± 0.8. The competing risk-adjusted 15-year patency rate of the NT-SV composite grafts was 91.7%, not significantly different from that of the arterial composite grafts in the TAC group (84.8%; P = .144). In addition, there were no significant differences in absolute 15-year patency rates of overall and composite grafts between the 2 groups. Clinical outcomes, such as overall survival and cumulative incidence of major adverse cardiac events up to 18 years, were not significantly different between the 2 groups. Propensity score matching yielded 176 pairs of patients from the 2 groups. There were no significant differences in either 15-year graft patency or 18-year clinical outcomes between the propensity score-matched groups. CONCLUSIONS: Results of CABG using the NT-SV composite grafts were comparable to those of CABG using arterial composite grafts in terms of 15-year patency and 18-year clinical outcomes.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hwang HY, Cho H, Sohn SH, et al. Fifteen-year patency and 18-year clinical outcomes after surgical revascularization using saphenous vein composite grafts to total arterial grafts. J Thorac Cardiovasc Surg. 2026. PMID: 42081970. doi:10.1016/j.jtcvs.2026.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。